-
Product Insights
EAMC – East Alabama Mental Healthcare Center – Alabama
The EAMC – East Alabama Mental Healthcare Center – Alabama involves the construction of a 5,016m2 40-bed freestanding psychiatric hospital in the Village Professional Park, East Alabama, Opelika, Alabama, the US. Equip yourself with the essential tools needed to make informed and profitable decisions with our EAMC – East Alabama Mental Healthcare Center – Alabama report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of...
-
Product Insights
CAMH – Toronto Mental Health Hospital Phase 1D Redevelopment – Ontario
The CAMH – Toronto Mental Health Hospital Phase 1D Redevelopment – Ontario involves the redevelopment of two buildings comprising a 33-bed mental health facility in Toronto, Ontario, Canada. Equip yourself with the essential tools needed to make informed and profitable decisions with our CAMH – Toronto Mental Health Hospital Phase 1D Redevelopment – Ontario report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the...
-
Company Insights
NewMindX Sciences Inc Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our MindX Sciences Inc Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. MindX Sciences Inc specializes in mental health management. The company is involved in the development and provision of mental health solutions aimed at assisting healthcare providers in making accurate diagnoses and treatment choices. It provides RNA blood tests, which are designed to assess disease state and risk, aid in diagnosis, and track response to treatment. The company is headquartered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Schizoaffective Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Schizoaffective Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Schizoaffective Disorder Drug Details: Lumateperone tosylate (Caplyta)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Major Depressive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Major Depressive Disorder Drug Details: Lumateperone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Bipolar II Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Bipolar II Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Bipolar II Disorder Drug Details: Lumateperone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lumateperone Tosylate in Bipolar I Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lumateperone Tosylate in Bipolar I Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lumateperone Tosylate in Bipolar I Disorder Drug Details: Lumateperone...
-
Thematic Analysis
NewHealth and Wellness in Insurance – Thematic Intelligence
This report explores how insurers are adapting to heightened interest in health and wellbeing. It examines the state of the market for individual policies and group policies separately, covering key market drivers and consumers’ degree of concern around different health and wellbeing aspects. It examines how businesses and employees view different employee benefits, with a focus on those traditionally offered by insurance providers. The report also examines how the industry has responded in terms of new product innovations and which...
-
Product Insights
NewKoa Health BV Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Koa Health BV Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Koa Health BV (Koa Health) is a digital mental healthcare provider that offers digital wellbeing and therapeutics solutions for mental health disorders. It's headquartered in Amsterdam, North-Holland, The Netherlands. GlobalData's Medical Devices company profile report, “Koa Health BV Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile...
-
Sector Analysis
NewUnited Kingdom (UK) Critical Illness Insurance Distribution Dynamics and Future Market
United Kingdom (UK) Critical Illness Insurance Market Report Overview The COVID-19 pandemic has left a lasting impact on consumers, highlighting the importance of mental and physical well-being and boosting awareness around the advantages of critical illness coverage. The total critical illness insurance market premiums was GBP28.7 million in 2022 and it will grow at a CAGR of more than 7% from 2022 to 2027. The UK critical illness insurance market research report explores consumer purchasing behaviors for critical illness insurance...